(ICU) SeaStar Medical Holding Corporation Business Model Canvas Research

SeaStar Medical Holding Corporation relies on contract manufacturers to scale assembly, enforce quality control, and keep its extracorporeal devices consistent. For regulated, sterile products like QUELIMMUNE, sterilization and component suppliers are critical because even one missed lot can disrupt supply continuity and patient treatment.

• Scale-up and assembly support
• Sterile components and sterilization
• Supply continuity and consistency

Regulatory advisors help SeaStar Medical Holding Corporation manage FDA strategy, clinical documentation, and compliance, while reimbursement partners support CPT, ICD-10, and CMS coverage work so approved devices can reach routine hospital use. In medtech, hospital procurement can take 6-12 months or longer, so these ties shape both approval and revenue timing.

• FDA path support
• Coverage and coding help
• Hospital buying cycle access

SeaStar Medical Holding Corporation’s manufacturing and supply chain QA is critical because its extracorporeal ICU devices must work reliably on every lot, every time. Tight control of materials, assembly, testing, and final release lowers shortage risk and helps protect performance in high-acuity care.

• Lot traceability matters in ICU devices.
• Supplier QA reduces part failures.
• Final release gates patient safety.

SeaStar Medical Holding Corporation’s hospital adoption depends on clinical education: physicians and ICU staff must learn patient selection and device use, while field teams support onboarding, in-service training, and troubleshooting. This matters because utilization and repeat ordering usually rise only after the device is embedded in ICU workflow.

• Train clinicians on use and selection
• Support onboarding and troubleshooting
• Drive utilization and repeat orders

SeaStar Medical Holding Corporation is headquartered in Denver, Colorado, and the site supports management, strategy, finance, and operating coordination. In 2025, the Company reported a net loss of $19.1 million, underscoring how the Denver base helps control cash, planning, and execution while clinical and commercial work runs nationwide.

• Denver anchors corporate control
• Supports finance and strategy
• National clinical and commercial reach

SeaStar Medical Holding Corporation’s key resources are cash, financing access, and commercialization infrastructure, because a development-stage device company needs funding to run trials, hire staff, build manufacturing, and support launch work. Without steady capital, the pipeline stalls and adoption stays limited.

• Cash funds trials and operations.
• Financing access extends runway.
• Commercial setup supports launch and scale.

SeaStar Medical Holding Corporation’s platform targets 4 critical care indications: pediatric and adult acute kidney injury, cardiorenal syndrome, myocardial stunning, and hepatorenal syndrome. That widens the addressable ICU market across nephrology, cardiology, and liver care, while a multi-indication model can improve commercial leverage as each use case adds clinical reach.

• 4 critical care indications
• Broader ICU specialty coverage
• Multi-indication commercial leverage

By reducing inflammatory injury, SeaStar Medical Holding Corporation’s therapy aims to protect kidneys, heart, and liver when they are under acute stress. Acute kidney injury affects about 20% of hospitalized adults and up to 50% of ICU patients, so better organ support can cut complications and shorten length of stay.

• Targets inflammation-driven organ injury
• Most relevant in acute stress cases
• May reduce complications and stay length

Hospital accounts are complex: a single SeaStar Medical Holding Corporation sale can require buy-in from ICU, nephrology, procurement, and administration. Dedicated account management helps move contract talks, lift utilization, and fit the device into local care pathways for critically ill AKI patients on CRRT.

• 4 stakeholder groups to align
• Contracting drives adoption
• Pathway fit boosts use

SeaStar Medical Holding Corporation’s post-market safety support means ongoing surveillance, complaint handling, and outcome tracking after launch. In regulated device markets, this keeps performance data flowing back from real use, which helps spot safety issues early and supports repeat use and broader rollout.

• Tracks device performance after launch
• Handles complaints and adverse events
• Builds trust for repeat use
• Supports wider clinical adoption

KOL and investigator networks fit SeaStar Medical Holding Corporation well because adoption in critical care often starts with trusted ICU leaders, and SeaStar Medical’s evidence base can spread fastest through clinicians who see severe AKI and sepsis cases every day. In niche hospital markets, even a small group of 10 to 20 influential investigators can shape protocol use, data capture, and peer-to-peer uptake.

• Trusted ICU leaders drive early use
• Investigators share practical outcomes
• Best for small critical care niches

SeaStar Medical Holding Corporation uses its website and medical affairs team as low-friction channels for clinicians and hospital staff, with digital touchpoints handling company info, product education, and contact capture while scientific questions are routed to the right experts. This matters most in hospital care, where fast, clear access can shorten the path from interest to clinical discussion.

• Website: info, education, lead capture
• Medical affairs: route scientific inquiries
• Best for clinicians and hospital staff

Liver and transplant centers are a key target because hepatorenal syndrome and other acute kidney injuries can hit up to 30% of hospitalized cirrhosis patients, and transplant teams manage the highest-risk multi-organ failure cases. SeaStar Medical Holding Corporation can fit into this critical care path by serving a new specialty that already handles high-acuity liver patients.

• High HRS and AKI burden
• Multi-organ failure risk
• New critical care use case

Critical care hospital systems are SeaStar Medical Holding Corporation’s best-fit buyers because one IDN can span dozens of ICUs and service lines, so a single win can open multiple use cases. In FY2025, this matters even more as the company targets system-level adoption to turn one clinical proof point into faster volume across large hospital networks.

• One account can cover many ICUs.
• Adoption can scale after proof.
• Fits nephrology and ICU workflows.

Manufacturing and supply chain remain a heavy cost center for SeaStar Medical Holding Corporation because production, materials, sterilization, and logistics all add recurring spend. For a regulated ICU device, small-batch output keeps unit costs high until volume scales, and any supplier or sterilization delay can disrupt treatment when demand cannot wait.

• High fixed cost per small batch
• Sterilization and logistics add spend
• Supply breaks can hit ICU care

SeaStar Medical Holding Corporation’s commercial launch needs field teams, medical education, and account managers, so sales, marketing, and support stay cash-heavy before scale. These costs are recurring because post-sale training and hospital support do not stop after first use, and they rise as the company enters new hospital segments.

• Field sales drives launch adoption.
• Education creates recurring spend.
• Support grows with each new hospital segment.

SeaStar Medical Holding Corporation can bundle implementation, training, and technical support into each commercial sale, so service and training fees can add high-margin, recurring income around the QUELIMMUNE launch. This also helps retention, because hospitals that pay for onboarding and support are more likely to keep using the system.

• Bundle setup, training, support
• Monetize onboarding directly or indirectly
• Raise switching costs for hospitals

As of SeaStar Medical's latest reported filings, product revenue was still immaterial, so partner milestones and royalties can be a useful non-dilutive cash source while the pipeline grows. In deals that split development, distribution, or indication expansion, even small royalty rates can add meaningful income before sales scale.

• Milestones can fund R&D
• Royalties can outlast launch
• Partners reduce cash burn